TY - JOUR
T1 - NIR-Responsive Methotrexate-Modified Iron Selenide Nanorods for Synergistic Magnetic Hyperthermic, Photothermal, and Chemodynamic Therapy
AU - Thirumurugan, Senthilkumar
AU - Muthiah, Kayalvizhi Samuvel
AU - Lin, Yu Chien
AU - Dhawan, Udesh
AU - Liu, Wai Ching
AU - Wang, An Ni
AU - Liu, Xinke
AU - Hsiao, Michael
AU - Tseng, Ching Li
AU - Chung, Ren Jei
N1 - Publisher Copyright:
© 2024 The Authors. Published by American Chemical Society
PY - 2024/5/22
Y1 - 2024/5/22
N2 - Breast cancer is a malignant tumor with a high mortality rate among women. Therefore, it is necessary to develop novel therapies to effectively treat this disease. In this study, iron selenide nanorods (FeSe2 NRs) were designed for use in magnetic hyperthermic, photothermal, and chemodynamic therapy (MHT/PTT/CDT) for breast cancer. To illustrate their efficacy, FeSe2 NRs were modified with the chemotherapeutic agent methotrexate (MTX). MTX-modified FeSe2 (FeSe2-MTX) exhibited excellent controlled drug release properties. Fe2+ released from FeSe2 NRs induced the release of •OH from H2O2 via a Fenton/Fenton-like reaction, enhancing the efficacy of CDT. Under alternating magnetic field (AMF) stimulation and 808 nm laser irradiation, FeSe2-MTX exerted potent hyperthermic and photothermal effects by suppressing tumor growth in a breast cancer nude mouse model. In addition, FeSe2 NRs can be used for magnetic resonance imaging in vivo by incorporating their superparamagnetic characteristics into a single nanomaterial. Overall, we presented a novel technique for the precise delivery of functional nanosystems to tumors that can enhance the efficacy of breast cancer treatment.
AB - Breast cancer is a malignant tumor with a high mortality rate among women. Therefore, it is necessary to develop novel therapies to effectively treat this disease. In this study, iron selenide nanorods (FeSe2 NRs) were designed for use in magnetic hyperthermic, photothermal, and chemodynamic therapy (MHT/PTT/CDT) for breast cancer. To illustrate their efficacy, FeSe2 NRs were modified with the chemotherapeutic agent methotrexate (MTX). MTX-modified FeSe2 (FeSe2-MTX) exhibited excellent controlled drug release properties. Fe2+ released from FeSe2 NRs induced the release of •OH from H2O2 via a Fenton/Fenton-like reaction, enhancing the efficacy of CDT. Under alternating magnetic field (AMF) stimulation and 808 nm laser irradiation, FeSe2-MTX exerted potent hyperthermic and photothermal effects by suppressing tumor growth in a breast cancer nude mouse model. In addition, FeSe2 NRs can be used for magnetic resonance imaging in vivo by incorporating their superparamagnetic characteristics into a single nanomaterial. Overall, we presented a novel technique for the precise delivery of functional nanosystems to tumors that can enhance the efficacy of breast cancer treatment.
KW - alternating magnetic field (AMF)
KW - chemodynamic therapy (CDT)
KW - magnetic hyperthermia therapy (MHT)
KW - methotrexate (MTX)
KW - photothermal therapy (PTT)
UR - http://www.scopus.com/inward/record.url?scp=85193050873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193050873&partnerID=8YFLogxK
U2 - 10.1021/acsami.3c18450
DO - 10.1021/acsami.3c18450
M3 - Article
C2 - 38739745
AN - SCOPUS:85193050873
SN - 1944-8244
VL - 16
SP - 25622
EP - 25636
JO - ACS Applied Materials and Interfaces
JF - ACS Applied Materials and Interfaces
IS - 20
ER -
